Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Market Sees Advances In CGMs, Artificial Pancreas Systems, And Connectivity

Executive Summary

The focus of the diabetes market is firmly on the development of an artificial pancreas, now within two or three years from becoming commercialized, and progress is going so well that several companies are in line to release a product. Meanwhile, digital health is increasingly playing a major role in diabetes care, and device manufacturers are investing in connectivity solutions to satisfy patient and consumer needs.

Advertisement

Related Content

Senseonics Rolls Out Eversense Subcutaneous Continuous Glucose Monitor
Medtronic Launches Advanced Chronic Pain Management System
AdvaMed 2015: Innovation Spotlight On Diabetes, Heart Failure Start-Ups
The Digital Health Care Revolution Picks Up Speed
New Product Briefs
FDA Approves Animas’ Vibe Linking Insulin Pump With DexCom CGM
ADA 2014: Diabetes Players Move Closer To An Artificial Pancreas

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT035929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel